

2-14-00

BoxSeq A

Docket # PF-0309-3 DIV

4/a
S.Q.J.
5/12/00



"Express Mail" mailing label number EL 001 834 045 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 16 Feb 2000

By: Larry W. Chaffee

Printed: Nancy Ramos Larry W. Chaffee

jc678 U.S. PTO
09/501714
02/10/00



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)**

Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No.09/388,993, filed on September 2, 1999, which is a divisional application of U.S. application Serial No.09/235,373, filed on January 20, 1999, issued December 14, 1999, as U.S. Patent No. 6,001,598, which is a divisional application of U.S. application Serial No. 08/868,288, filed June 3, 1997, issued July 13, 1999, as U.S. Patent No. 5,922,567, all entitled **TWO NEW HUMAN DNAJ-LIKE PROTEINS**

1. Enclosed is a copy of the prior application, U.S. application Serial No. 08/868,288, filed June 3, 1997, including the oath or declaration as originally filed.
2. Enclosed herewith is a substitute paper copy of the Sequence Listing.
- With regard to the requirement of 37 CFR 1.821(d) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants hereby submit a computer readable form of the "Substitute Sequence Listing" filed with the instant divisional application.
- Cancel in this application original claims 1-42 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
4. The inventors of the invention being claimed in this application are: Janice Au-Young, Preeti Lal, and Olga Bandman.
5. In accordance with 37 CFR 1.63(d) a copy of the originally signed declaration showing applicants' signatures as filed on November 24, 1997, is enclosed.

- 20 6/16/00*
- R*
6. Amend the specification by inserting before the first line the sentence: "This application is a divisional application of U.S. application Serial No.09/388,993, filed on September 2, 1999, now Pat 6,043,222 which is a divisional application of U.S. application Serial No.09/235,373, filed on January 20, 1999, issued December 14, 1999, as U.S. Patent No. 6,001,598, which is a divisional application of U.S. application Serial No. 08/868,288, filed June 3, 1997, issued July 13, 1999, as U.S. Patent No. 5,922,567."

7. The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity Rate		Basic Fee \$690.00
				Fee	Fee	
Total Claims	23	-20	3	x \$18		\$ 54
Indep. Claims	2	-3	0	x \$78		\$ 0
<u>Multiple Dependent Claim(s), if any</u>				+ \$260		\$ 0

TOTAL FILING FEE \$ 744.00

8. An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
9. Please charge Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108 in the amount of \$ 744.00.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Incyte Pharmaceuticals, Inc. Account No. 09-0108.

A duplicate copy of this Request is enclosed.

10. New formal drawings are enclosed.
11. The prior application is assigned of record to Incyte Pharmaceuticals, Inc., recorded on April 27, 1998, at reel 9158/frame 0524.
12. A preliminary amendment is enclosed.
13. Also enclosed: Return Postcard, Submission of Sequence Listing, Information Disclosure Statement, List of Cited References (1449), Submission of Formal Drawings, and copy of Revocation of Power of Attorney and Appointment of New Attorneys.
14. The power of attorney of the prior application is to:

14. X The power of attorney of the prior application is to:

Narinder S. Banait	Reg. No. 43,482
Adam Warwick Bell	Reg. No. 43,490
Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Colette C. Muenzen	Reg. No. 39,784
Lynn E. Murry	Reg. No. 42,918
Danielle M. Pasqualone	Reg. No. 43,847
Susan K. Sather	Reg. No. 44,316
David G. Streeter	Reg. No. 43,168

 The associate power of attorney in the prior application is to:

- a. An associate power of attorney is attached.
- b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. X Address all future correspondence to:

INCYTE PHARMACEUTICALS, INC.
PATENT DEPARTMENT
3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555, Fax: (650) 849-8886

Date: February 7, 2003 By:



David G. Streeter, Ph. D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

 Inventor(s)


 Assignee of complete interest


X Attorney or agent of record

 Filed under 37 CFR 1.34(a)

Registration number if acting under 37 CFR 1.34(a) _____

"Express Mail" mailing label number EL 001 834 045 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on 10 Feb 2000

By: 

Printed: Nancy Rames 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Au-Young et al.

Title: TWO NEW HUMAN DNAJ-LIKE PROTEINS

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Assistant Commissioner for Patents
Box Sequence
Washington, D.C. 20231

SUBMISSION UNDER 37 CFR § 1.821-1.825 SEQUENCE LISTING

Sir:


In accordance with the requirements of 37 CFR § 1.821-1.825, Applicants hereby submit one diskette containing the computer-readable information for the Substitute Sequence Listing of the above-identified application. The diskette complies with the requirements of 37 CFR § 1.824 and is IBM PC compatible using a PC-DOS/MS-DOS 6.2 operating system with Fastseq software version 2.0.

Accompanying the application is the paper copy of the Substitute Sequence Listing as disclosed in the application.

The content of the Substitute Sequence Listing paper copy is identical to the computer-readable copy, as required under 37 CFR § 1.821(f).

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.



David G. Streeter, Ph. D.

Reg. No. 43,168

Direct Dial Telephone: (650) 845-5741

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

"Express Mail" mailing label number EL 001 834 045 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 10 Feb. 2000

By: W. Clark
Printed: Debbie Ellis Warrlyn Clark

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Au-Young et al.

Title: TWO NEW HUMAN DNAJ-LIKE PROTEINS

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

SUBMISSION OF FORMAL DRAWINGS

Sir:

Transmitted herewith are Figures 1A, 1B, 1C, 1D, 2A, 2B, 3A, 3B, 3C, 3D, 4A and 4B as twelve (12) sheets of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the reverse side of the drawings.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**. A **duplicate copy of this communication is enclosed**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at (650) 845-5741.

Respectfully submitted,
INCYTE PHARMACEUTICALS, INC.

Date: February 9, 2000

David G. Streeter
David G. Streeter, Ph. D.
Reg. No. 43,168
Direct Dial Telephone: (650) 845-5741

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 845-4813
Fax: (650) 849-8886